Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review

Feelemyer, Jonathan; Jarlais, Don C. Des; Arasteh, Kamyar; Phillips, Benjamin; Hagan, Holly

doi:10.1016/j.drugalcdep.2013.10.011

Cited by 91 publications

(69 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, significant changes were observed in all subscales of WHOQOL -BREF, including physical health, psychological health, social relationship, and environmental health. These significant changes in both quality of life and addiction severity were similar to the results described in a multisite clinical trial, which assessed Opioid Substitution Treatment (OST) in 13 treatment programs in seven low and middle income countries (24). The quality of life and addiction severity scales are important findings that are associated with improved retention (25).…”

Section: Discussionsupporting

confidence: 66%

Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder

Shariatirad

Mahjoub

Haqiqi

et al. 2018

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

Background: Methamphetamine (MA) use remains a major public health concern around the world. Recent findings suggest that buprenorphine may be helpful for cocaine use reduction. Moreover, animal studies described reduced dopamine peak effect following MA use, due to the administration of low dose buprenorphine. Objectives: This study examined the effectiveness of buprenorphine with brief cognitive behavioral therapy on MA use disorder. Methods: The study was conducted in an outpatient substance abuse treatment center in Qazvin, Iran. Nineteen MA users received buprenorphine for 24 weeks combined with brief cognitive behavioral therapy in an outpatient substance abuse treatment program, three times per week, as a before and after non -randomization study. Clinical outcomes included treatment retention, MA use, degree of MA dependency and craving, quality of life, cognitive abilities questionnaire, addiction severity and also adverse events. Data was analyzed by performing repeated measures analysis and the Friedman test for nonparametric variables. Results: Fifteen participants completed the study during six months and frequency of MA use was significantly decreased at 24 weeks (P < 0.001). There were also significant reductions in craving (P < 0.001), degree of MA dependence (P < 0.001), and improvements in quality of life, cognitive ability, and some subscales of addiction severity. Conclusions:The results of this preliminary clinical study demonstrated that buprenorphine could potentially attenuate MA craving and alternate rewarding effects of MA and had promising effects on cognitive impairment. Furthermore, buprenorphine can be considered as a harm reduction intervention in some communities, in which the people, as a result of cultural beliefs, do not accept a therapy, which only consists of counseling and no medications.

show abstract

Section: Discussionsupporting

confidence: 66%

Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder

Shariatirad

Mahjoub

Haqiqi

et al. 2018

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

show abstract

“…Medication assisted therapy, such as buprenorphine/ naloxone, reduces rates of overdose and overdose death [41][42][43], reduces recidivism in emergency departments and within the criminal justice system [44,45], increases compliance and adherence to other medical services [31,32]. But most importantly, it helps put people on the path to recovery and enhances their quality of life [46,47].…”

Section: Resultsmentioning

confidence: 99%

Individualizing Opioid Use Disorder (OUD) Treatment: Time to Fully Embrace a Chronic Disease Model

Gustin¹,

Nichols²,

Martin³

2015

J Reward Defic Syndr

View full text Add to dashboard Cite

The current opioid epidemic in the United States is changing our perceptions of the face of addiction. Opioid Use Disorder (OUD) has become pervasive and is affecting all ethnicities, races, socioeconomic classes, the young and the old. In 2015, 46 people will lose their life each day to a chronic brain disease that is going unnoticed and undertreated. Over the last five decades, numerous scientific and clinical breakthroughs have allowed for a better understanding of the mechanisms underlying addiction, and the development of medications that can help support a patient's long-term recovery. All of those that have contributed to these advancements have aided in redefining addiction as a primary, chronic disease of the brain reward, motivation, memory and related circuitry; however, our treatment strategies have not necessarily advanced to the same extent as our current understanding of the disease. This commentary will explore how personal philosophies can bias treatments strategies and definitions of treatment success, and prevent adoption of chronic disease treatment models that would significantly improve the quality of life of those suffering with OUD. This is a challenge to consider how our views and stigma can impact a patient's recovery. We are currently losing a battle with a disease that is taking the lives of 46 individuals daily; it is time to fully embrace a chronic disease model which comprises an integrated pharmacopsychosocial approach for treating the biopsychosocial disorder that is addiction to reverse these trends.

show abstract

“…The WHOQOL-BREF has proven to be an instrument that is sensitive to the changes caused by treatment, with methadone (Feelemyer, Des Jarlais, Arasteh, Phillips, & Hagan, 2014) and without (Sánchez-Hervás, Tomás-Gradolí, Molina Bou, del Olmo Gurrea, & Morales Gallús, 2002). In general, the findings show that people improve their quality of life when they stop using non-prescribed opiates and undergo treatment with methadone (Padaiga, Subata, & Vanagas, 2007).…”

Section: Introductionmentioning

confidence: 63%

Quality of life in patients treated with methadone: The WHOQOL-BREF, psychometric study and application results

Pérez

2018

AN PSICOL-SPAIN

View full text Add to dashboard Cite

Título: Calidad de vida en pacientes tratados con metadona: el WHO-QOL-BREF, estudio psicométrico y resultados de aplicación. Resumen: Objetivo. De entre los muchos instrumentos propuestos para medir la calidad de vida de los pacientes con adicción a opiáceos tratados con metadona el WHOQOL-BREF, propuesto por la World Health Organization, es el que más se utiliza en la actualidad. Este trabajo pretende estudiar la fiabilidad y la validez de constructo de la prueba, aplicada a una muestra amplia y representativa de pacientes, y comparar los resultados con los datos disponibles para población general en España. Se reclutó una muestra de 523 sujetos que se encontraban en tratamiento con metadona, en Madrid y Extremadura. Se efectuó un análisis factorial confirmatorio para probar la estructura teóricamente propuesta y, seguidamente, un análi-sis paralelo optimizado para conocer el número más adecuado de componentes de la prueba. Los resultados muestran que la prueba presenta sóli-dos valores de consistencia interna, tanto a nivel del ítem como de las escalas. La estructura tetradimensional teórica se confirma en la muestra con adecuados indicadores de ajuste, aunque también se obtienen serios argumentos para considerar su unidimensionalidad. Se estudió la relación estructural entre los cuatro dominios. El WHOQOL-BREF se muestra como una prueba fiable y válida para su uso en pacientes tratados con metadona, proporcionando una medida multidimensional de la calidad de vida percibida, que incluye factores sociales y ambientales ausentes en otros instrumentos, que son de enorme importancia en el tratamiento de los problemas adictivos. Palabras clave: Calidad de vida; WHOQOL-BREF; Tratamiento con metadona; Propiedades psicométricas; Análisis estructural; Adicción. Abstract:The most commonly instrument used to measure quality of life in patients with addictive behaviors is the WHOQOL-BREF, developed by the World Health Organization. No studies have been found to explore the psychometric properties in Spanish clinical samples. This paper aims to study their reliability as well as the construct validity in a representative sample of patients and comparing the results to the data available for the general population in Spain. A sample was recruited comprised of 523 subjects who were undergoing treatment with methadone in Madrid and Extremadura. A confirmatory factor analysis was completed to test the theoretically proposed structure and then an optimized-parallel analysis was done to establish the most adequate number of components. The result offers solid values for internal consistency both as concerns the items and the scales. The theoretical tetra-dimensional structure is confirmed in the sample although serious arguments are also found for considering its onedimensionality. The structural relationship between the four domains was studied. The WHOQOL-BREF proves to be a reliable and valid test for use on patients treated with methadone, providing a multi-dimensional measure of perceived quality of life that includes soci...

show abstract

Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: An international systematic review

Cited by 91 publications

References 49 publications

Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder

Buprenorphine Added on Brief Cognitive Behavioral Therapy for Treatment of Methamphetamine Use Disorder

Individualizing Opioid Use Disorder (OUD) Treatment: Time to Fully Embrace a Chronic Disease Model

Quality of life in patients treated with methadone: The WHOQOL-BREF, psychometric study and application results

Contact Info

Product

Resources

About